Who Buys Canagliflozin from India — 66 Importers Behind a $883.4K Market

The 66 buyers of Canagliflozin from India can be categorized into the following segments:

• Distributors: Entities like SUCCESS INTER LINK PTE LTD and VERONA PHARMACY PTE LTD in Singapore likely function as distributors, purchasing large quantities to supply to various healthcare providers. Their order patterns typically involve bulk purchases to maintain a steady supply chain.

• Re-exporters: Companies such as BPOST INTERNATIONAL in Belgium and TRANS SPED AG - SMI in Switzerland may act as re-exporters, importing Canagliflozin for redistribution to other markets. This segment often places orders based on demand fluctuations in their target export destinations.

• Retail Chains: Entities like TO THE- in Singapore and RIGHT AND BRIGHT INTERNATIONAL in Myanmar are likely retail chains, procuring Canagliflozin to stock their pharmacies. Their purchasing behavior is influenced by consumer demand and inventory turnover rates.

• Government Procurement: While not explicitly listed among the top buyers, government agencies or organizations involved in national tenders may also import Canagliflozin to supply public healthcare facilities. Their orders are typically large and periodic, aligned with budget cycles and public health initiatives.

For the top five importing countries, the import regulations for Canagliflozin are as follows:

• Singapore:
• Regulatory Authority: Health Sciences Authority (HSA)
• Import Registration Process: Importers must obtain a product license from the HSA, which involves submitting comprehensive documentation, including clinical data and manufacturing details.
• Estimated Timeline: The registration process typically takes 9 to 12 months.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally exempt from import duties in Singapore.

• Mauritius:
• Regulatory Authority: Pharmacy Board under the Ministry of Health and Wellness
• Import Registration Process: Importers are required to register pharmaceutical products with the Pharmacy Board, providing necessary documentation for evaluation.
• Estimated Timeline: The registration process can take approximately 6 to 9 months.
• Import Tariff/Duty: Mauritius imposes a 15% Value Added Tax (VAT) on pharmaceutical products; however, specific import duties may vary.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP)
• Import Registration Process: Pharmaceutical products must be authorized by the FAMHP, requiring submission of a marketing authorization application.
• Estimated Timeline: The process usually takes 12 to 15 months.
• Import Tariff/Duty: As an EU member, Belgium applies a common external tariff; however, pharmaceutical products often benefit from reduced or zero tariffs.

• Switzerland:
• Regulatory Authority: Swiss Agency for Therapeutic Products (Swissmedic)
• Import Registration Process: Importers must obtain marketing authorization from Swissmedic, involving a thorough review of the product's safety and efficacy.
• Estimated Timeline: The registration process can take between 10 to 14 months.
• Import Tariff/Duty: Switzerland generally exempts pharmaceutical products from import duties.

• Taiwan:
• Regulatory Authority: Taiwan Food and Drug Administration (TFDA)
• Import Registration Process: A product registration with the TFDA is mandatory, requiring detailed documentation and compliance with local regulations.
• Estimated Timeline: The registration process typically spans 8 to 12 months.
• Import Tariff/Duty: Pharmaceutical imports under HS Code 30049099 are subject to a 5% import duty in Taiwan.

The demand for Canagliflozin in importing countries is primarily driven by the prevalence of type 2 diabetes mellitus (T2DM). According to the World Health Organization (WHO), the global prevalence of diabetes among adults was 8.5% in 2024, with significant increases observed in regions like Southeast Asia and the Western Pacific. Government healthcare programs aimed at managing and treating diabetes, along with the expansion of universal health coverage, have further bolstered the demand for effective antidiabetic medications like Canagliflozin.

Additionally, procurement through WHO's Essential Medicines List and tender-based purchasing mechanisms have facilitated the accessibility of Canagliflozin in various markets. The presence of 66 buyers across 23 countries indicates a broad and growing market for this medication, reflecting its critical role in diabetes management strategies worldwide.

The 66 buyers of Canagliflozin from India can be categorized into the following segments:

• Distributors: Entities like SUCCESS INTER LINK PTE LTD and VERONA PHARMACY PTE LTD in Singapore likely function as distributors, purchasing large quantities to supply to various healthcare providers. Their order patterns typically involve bulk purchases to maintain a steady supply chain.

• Re-exporters: Companies such as BPOST INTERNATIONAL in Belgium and TRANS SPED AG - SMI in Switzerland may act as re-exporters, importing Canagliflozin for redistribution to other markets. This segment often places orders based on demand fluctuations in their target export destinations.

• Retail Chains: Entities like TO THE- in Singapore and RIGHT AND BRIGHT INTERNATIONAL in Myanmar are likely retail chains, procuring Canagliflozin to stock their pharmacies. Their purchasing behavior is influenced by consumer demand and inventory turnover rates.

• Government Procurement: While not explicitly listed among the top buyers, government agencies or organizations involved in national tenders may also import Canagliflozin to supply public healthcare facilities. Their orders are typically large and periodic, aligned with budget cycles and public health initiatives.

For the top five importing countries, the import regulations for Canagliflozin are as follows:

• Singapore:
• Regulatory Authority: Health Sciences Authority (HSA)
• Import Registration Process: Importers must obtain a product license from the HSA, which involves submitting comprehensive documentation, including clinical data and manufacturing details.
• Estimated Timeline: The registration process typically takes 9 to 12 months.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally exempt from import duties in Singapore.

• Mauritius:
• Regulatory Authority: Pharmacy Board under the Ministry of Health and Wellness
• Import Registration Process: Importers are required to register pharmaceutical products with the Pharmacy Board, providing necessary documentation for evaluation.
• Estimated Timeline: The registration process can take approximately 6 to 9 months.
• Import Tariff/Duty: Mauritius imposes a 15% Value Added Tax (VAT) on pharmaceutical products; however, specific import duties may vary.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP)
• Import Registration Process: Pharmaceutical products must be authorized by the FAMHP, requiring submission of a marketing authorization application.
• Estimated Timeline: The process usually takes 12 to 15 months.
• Import Tariff/Duty: As an EU member, Belgium applies a common external tariff; however, pharmaceutical products often benefit from reduced or zero tariffs.

• Switzerland:
• Regulatory Authority: Swiss Agency for Therapeutic Products (Swissmedic)
• Import Registration Process: Importers must obtain marketing authorization from Swissmedic, involving a thorough review of the product's safety and efficacy.
• Estimated Timeline: The registration process can take between 10 to 14 months.
• Import Tariff/Duty: Switzerland generally exempts pharmaceutical products from import duties.

• Taiwan:
• Regulatory Authority: Taiwan Food and Drug Administration (TFDA)
• Import Registration Process: A product registration with the TFDA is mandatory, requiring detailed documentation and compliance with local regulations.
• Estimated Timeline: The registration process typically spans 8 to 12 months.
• Import Tariff/Duty: Pharmaceutical imports under HS Code 30049099 are subject to a 5% import duty in Taiwan.

The demand for Canagliflozin in importing countries is primarily driven by the prevalence of type 2 diabetes mellitus (T2DM). According to the World Health Organization (WHO), the global prevalence of diabetes among adults was 8.5% in 2024, with significant increases observed in regions like Southeast Asia and the Western Pacific. Government healthcare programs aimed at managing and treating diabetes, along with the expansion of universal health coverage, have further bolstered the demand for effective antidiabetic medications like Canagliflozin.

Additionally, procurement through WHO's Essential Medicines List and tender-based purchasing mechanisms have facilitated the accessibility of Canagliflozin in various markets. The presence of 66 buyers across 23 countries indicates a broad and growing market for this medication, reflecting its critical role in diabetes management strategies worldwide.